Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis

Rheumatoid arthritis (RA) is an autoimmune synovitis characterized by the formation of pannus and the destruction of cartilage and bone in the synovial joints. Although immune cells, which infiltrate the pannus and promote inflammation, play a prominent role in the pathogenesis of RA, other cell typ...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of immunology (1950) Vol. 188; no. 7; pp. 3513 - 3521
Main Authors Swanson, Christina D, Akama-Garren, Elliot H, Stein, Emily A, Petralia, Jacob D, Ruiz, Pedro J, Edalati, Abdolhossein, Lindstrom, Tamsin M, Robinson, William H
Format Journal Article
LanguageEnglish
Published United States 01.04.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Rheumatoid arthritis (RA) is an autoimmune synovitis characterized by the formation of pannus and the destruction of cartilage and bone in the synovial joints. Although immune cells, which infiltrate the pannus and promote inflammation, play a prominent role in the pathogenesis of RA, other cell types also contribute. Proliferation of synovial fibroblasts, for example, underlies the formation of the pannus, while proliferation of endothelial cells results in neovascularization, which supports the growth of the pannus by supplying it with nutrients and oxygen. The synovial fibroblasts also promote inflammation in the synovium by producing cytokines and chemokines. Finally, osteoclasts cause the destruction of bone. In this study, we show that erlotinib, an inhibitor of the tyrosine kinase epidermal growth factor receptor (EGFR), reduces the severity of established collagen-induced arthritis, a mouse model of RA, and that it does so by targeting synovial fibroblasts, endothelial cells, and osteoclasts. Erlotinib-induced attenuation of autoimmune arthritis was associated with a reduction in number of osteoclasts and blood vessels, and erlotinib inhibited the formation of murine osteoclasts and the proliferation of human endothelial cells in vitro. Erlotinib also inhibited the proliferation and cytokine production of human synovial fibroblasts in vitro. Moreover, EGFR was highly expressed and activated in the synovium of mice with collagen-induced arthritis and patients with RA. Taken together, these findings suggest that EGFR plays a central role in the pathogenesis of RA and that EGFR inhibition may provide benefits in the treatment of RA.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Funding Sources National Institutes of Health (NIH) National Heart Lung and Blood Institute contract N01-HV-00242
NIH training grant 5 T32 AI07290 for Molecular and Cellular Immunobiology
NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases R01 AR-054822
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.1102693